The Janus Henderson Global Sustainable Equity Managed Account Portfolio returned -5.71% (gross) for Q4 2024. Click here to ...
The ATA wants to see Australia keep its technical design rules for trucks and heavy trailers, but believes our light vehicles ...
21h
CarExpert.com.au on MSNToyota Tarago successor axed due to new safety regulationToyota's slow-selling Granvia people mover has gotten the axe, leaving the brand without an option in a segment it once ...
Barclays (LON:BARC) maintained its Equalweight rating on Baidu (NASDAQ:BIDU) stock but increased the price target to $95.00 from the previous $83.00. The adjustment reflects a re-rating of the broader ...
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...
20hon MSN
We recently compiled a list of the 12 Best Stocks That Pay Monthly Dividends in 2025. In this article, we are going to take a ...
Pure Hydrogen, Solo Resource Recovery and the City of West Torrens Council have partnered to deliver Australia’s first HFC ...
Gathering at this week's 87th annual session of the UNECE Inland Transport Committee (ITC) at the Palais des Nations in Geneva, global transport ...
2d
CarsGuide.com.au on MSNLuxury SUV picks up 60km driving range plug-in hybrid: 2025 Lexus RX 450h+ PHEV confirmed to rival BMW X5 50e and Volkswagen Touareg RLexus has announced a second plug-in hybrid in its line-up. To be released in April 2025, the Lexus RX 450h+ PHEV costs $123,500, before on-road costs, and uses the same set-up as the smaller NX 450h+ ...
3d
Asian News International on MSNSMFG India Credit Wins the Prestigious Golden Peacock Award for Corporate Social Responsibility 2024SMFG India Credit has won the coveted Golden Peacock Award for Corporate Social Responsibility 2024. This prestigious ...
Rentokil operates a virtually non-cyclical and largely route-based business, with consequently great flexibility. Check out ...
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results